FDA Layoffs Spark Concern in Medtech Industry

Advamed CEO Warns of Risks to Patient Care and U.S. Leadership
Scott Whitaker, CEO of Advamed, has raised alarm over recent job cuts at the Food and Drug Administration (FDA), warning that these layoffs could significantly impact patient care and threaten the United States' position as a global leader in medical technology. In a letter to the Department of Health and Human Services (HHS), Whitaker called for the reversal of these staff reductions, arguing that they are at odds with the new administration's health goals.
The cuts, which occurred over a recent weekend, were reportedly planned before Robert F. Kennedy Jr. was sworn in as HHS Secretary. Whitaker expressed concern that these layoffs do not align with Kennedy's stated objective to "make America healthy again."
Trump Administration's Federal Workforce Reduction Plan
The FDA job cuts are part of a larger initiative by President Donald Trump to streamline the federal workforce. This effort is being carried out through the newly established Department of Government Efficiency (DOGE), led by businessman and Trump adviser Elon Musk. While Advamed supports the administration's aim to use taxpayer dollars more efficiently, Whitaker argues that the FDA layoffs may ultimately undermine this goal.
Impact on FDA Operations and Device Reviews
According to Whitaker, the FDA was already struggling to manage tens of thousands of annual device applications before these layoffs. Recent improvements in review times, attributed to the latest user fee agreement that incentivized agency efficiency, are now at risk. Whitaker stated, "Unfortunately, as a result of these reductions, FDA will lose hundreds of new employees, the best and most innovative hires under our most recent agreement."
Of particular concern is the elimination of critical hires in the FDA's artificial intelligence (AI) operation. This move could lead to non-experts being reassigned to review AI technologies, potentially slowing the process significantly and resulting in inappropriate decisions.
References
- Advamed CEO warns FDA job cuts put patients, industry at risk
Scott Whitaker sent a letter to HHS calling for staff cuts at the FDA to be reversed, arguing patient care and U.S. leadership in medical devices are on the line.
- Advamed CEO warns FDA job cuts put patients, industry at risk
Scott Whitaker sent a letter to the HHS calling for staff cuts at the FDA to be reversed, arguing patient care and U.S. leadership in medtech are on the line.
Explore Further
What impact have similar FDA personnel changes had on the agency's ability to handle device reviews in the past?
How might the elimination of AI-related hires at the FDA affect the future approval process for AI technologies in medtech?
What steps is Advamed taking to support the reinstatement of the FDA personnel positions that were cut?
How do the current FDA layoffs compare to workforce changes in similar regulatory agencies globally?
What is the historical relationship between the Trump administration's policies and staffing changes at the FDA?